Developer docs
API playgroundTry for free, no card

Search company profiles

FluGen

Full company profile

uuid0000zqh

Namestring
FluGen
Legal namestring
FluGen, Inc.
Websiteurl
flugen.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

FluGen is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Madison, Wisconsin. The company develops vaccines for the prevention and treatment of seasonal and pandemic influenza using its proprietary M2SR (M2 Deleted Single Replication) platform technology. M2SR is a live but replication-deficient influenza virus in which the M2 protein required for viral replication has been genetically deleted; the virus is delivered as an intranasal spray, stimulating mucosal, humoral, and cellular immunity without causing viral shedding or illness. The lead candidate has demonstrated protection across seven years of virus drift in a Phase 2 human challenge study, with results published in the Journal of Infectious Diseases.

The company pursues multiple vaccine candidates derived from the M2SR platform, including a universal influenza vaccine originally branded RedeeFlu, a quadrivalent formulation, an H5N1 avian influenza vaccine, and a bivalent COVID-19/influenza combination vaccine using M2SR as a vector for the SARS-CoV-2 receptor binding domain. The technology is exclusively licensed from the University of Wisconsin-Madison via WARF and was developed in the laboratories of co-founders Dr. Yoshihiro Kawaoka and Dr. Gabriele Neumann. FluGen operates a clinical-stage enterprise GTM motion centered on government and institutional partnerships — primarily with the U.S. Department of Defense and NIH/NIAID — which provide both non-dilutive grant funding and clinical trial collaboration infrastructure.

FluGen remains pre-revenue with no commercially approved products. Operations have been funded primarily through venture capital (most notably a $12 million Series A in 2015 led by Venture Investors LLC) and federal grants (including a $14.4 million Department of Defense award in October 2017 and additional DoD funding in 2021). Target customer segments for eventual commercialization are older adults aged 65+, pediatric populations aged 6 months to 17 years, and the general population, with distribution expected to flow through government procurement channels and healthcare provider networks upon regulatory approval.

Short descriptiontext

FluGen is a clinical-stage biopharmaceutical company developing intranasal influenza vaccines using its proprietary M2SR (M2 Deleted Single Replication) live virus platform, targeting older adults, pediatric populations, and the general population against seasonal and pandemic influenza strains.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMadison, United States
HQ citystring
Madison
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
influenza vaccine development, intranasal vaccine platform, universal flu vaccine, vaccine clinical trials, biopharmaceutical research
Industry3 codes
PRIMARYHLAIAEAD
Seasonal & Endemic Vaccines (e.g., Influenza)
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Influenza Vaccines
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Vaccine Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage company developing influenza vaccines. Revenue will be generated through vaccine product sales following regulatory approval. The company is developing multiple vaccine candidates including M2SR monovalent and quadrivalent formulations, as well as bivalent COVID/Influenza combination vaccines.

flugen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1M2SR
Description

M2 Deleted Single Replication live virus vaccine technology - the company's flagship supra-seasonal intranasal influenza vaccine candidate

flugen.com
+1 more record
Core offering1 text field

FluGen is a clinical-stage biopharmaceutical company developing the M2SR (M2 Deleted Single Replication) vaccine platform, a live, replication-deficient influenza virus delivered as an intranasal spray that stimulates mucosal, humoral, and cellular immunity. The company is advancing multiple vaccine candidates including a universal supra-seasonal influenza vaccine (formerly branded RedeeFlu), a quadrivalent M2SR formulation, an H5N1 avian influenza vaccine, and a bivalent COVID-19/influenza combination vaccine using M2SR as a vector platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • M2SR demonstrated protection against infection and illness across seven years of virus drift in Phase 2 challenge study
+2 more records
Product overview1 text field

FluGen is a clinical-stage vaccine company developing M2SR (M2 Deficient Single Replication), a live intranasal vaccine platform that works differently from standard flu vaccines. The flagship M2SR vaccine (also branded as RedeeFlu) stimulates mucosal, humoral, and cellular immunity and has demonstrated unprecedented protection across seven years of virus drift. The company is also leveraging M2SR as a vector platform for a bivalent COVID-19/Influenza combination vaccine. The development pipeline includes quadrivalent influenza vaccine formulations and M2SR variants targeting H5N1 avian influenza.

Product and service1 record
1M2SR Vaccine Platform
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1National Institute of Allergy and Infectious Diseases (NIAID) - CIVICs Program
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Pediatric clinical trial funded by NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) program. Study conducted at University of Maryland, Duke University, Vanderbilt University, and University of Iowa to evaluate M2SR in children ages 6 months to 17 years.

flugen.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-04-02
Description

International collaboration with Bharat Biotech to develop CoroFlu, a coronavirus vaccine candidate. Part of broader efforts to apply M2SR technology platform to COVID-19.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2013-07-01
Description

Partnership with UK-based Arecor to develop stable formulation for RedeeFlu vaccine using Arecor's Arestat formulation technology. Funded by UK's Technology Strategy Board Smart programme to improve storage, distribution, and nasal delivery stability.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-05-08
Description

WARF exclusively licensed FluGen's core M2SR influenza vaccine technology from UW-Madison. The technology was invented in the laboratories of Dr. Yoshihiro Kawaoka and Dr. Gabriele Neumann at UW-Madison and licensed to FluGen.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing oral tablet flu vaccines using a non-replicating adenoviral vector platform. Like FluGen, Vaxart pursues mucosal immunity against influenza via an alternative delivery route (oral vs. intranasal) and targets both seasonal and pandemic indications.

2BiondVax Pharmaceuticals
TypeDirect peer
Description

Israel-based clinical-stage developer of M-001, a recombinant universal flu vaccine candidate targeting conserved epitopes across influenza strains. BiondVax is the most direct competitor in the 'universal influenza vaccine' category alongside FluGen's M2SR.

TypeEmerging player
Description

Clinical-stage vaccine company spun out of Oxford University developing T-cell based influenza vaccines and other immunotherapies. Pursues broader cellular immunity against influenza, paralleling FluGen's cellular-immunity-driven approach with M2SR.

TypeBroad incumbent
Description

Public clinical-stage/commercial vaccine company using recombinant nanoparticle technology. Novavax's Matrix-M adjuvanted flu vaccine candidate competes in the broader enhanced-immunity influenza space that FluGen targets with M2SR.

TypeBroad incumbent
Description

mRNA vaccine leader advancing multiple influenza vaccine candidates including mRNA-1010 and combination flu/COVID programs. Moderna's mRNA flu pipeline represents the most significant emerging competitive threat to FluGen's next-generation influenza approach.

6Sanofi Pasteur
TypeBroad incumbent
Description

World's largest influenza vaccine manufacturer producing Fluzone High-Dose and other standard-of-care flu vaccines. Sanofi's established manufacturing, distribution, and physician relationships represent the dominant incumbent FluGen must displace to capture market share.

TypeBroad incumbent
Description

Major influenza vaccine manufacturer and developer of Fluad (MF59-adjuvanted vaccine) and cell-based flu vaccines. CSL Seqirus is a key incumbent competitor in enhanced-immunity influenza vaccines targeting older adults.

TypeRegional player
Description

India-based vaccine manufacturer and direct FluGen partner for the CoroFlu (COVID/Influenza) combination vaccine. Bharat Biotech is also an independent developer of influenza and other vaccines, making it both a peer and a commercial partner.

TypeBroad incumbent
Description

Owner of FluMist, the established intranasal live attenuated influenza vaccine. AstraZeneca is the most direct existing competitor in the intranasal flu vaccine category where FluGen's M2SR is positioned.

TypeEmerging player
Description

Plant-derived virus-like particle (VLP) vaccine developer with influenza candidates including a quadrivalent flu vaccine. Medicago pursues alternative vaccine production platforms similar to FluGen's novel M2SR approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FluGen

Influenza Vaccinesflugen.com

FluGen is a clinical-stage biopharmaceutical company developing intranasal influenza vaccines using its proprietary M2SR (M2 Deleted Single Replication) live virus platform, targeting older adults, pediatric populations, and the general population against seasonal and pandemic influenza strains.

What FluGen does

FluGen is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Madison, Wisconsin. The company develops vaccines for the prevention and treatment of seasonal and pandemic influenza using its proprietary M2SR (M2 Deleted Single Replication) platform technology. M2SR is a live but replication-deficient influenza virus in which the M2 protein required for viral replication has been genetically deleted; the virus is delivered as an intranasal spray, stimulating mucosal, humoral, and cellular immunity without causing viral shedding or illness. The lead candidate has demonstrated protection across seven years of virus drift in a Phase 2 human challenge study, with results published in the Journal of Infectious Diseases.

The company pursues multiple vaccine candidates derived from the M2SR platform, including a universal influenza vaccine originally branded RedeeFlu, a quadrivalent formulation, an H5N1 avian influenza vaccine, and a bivalent COVID-19/influenza combination vaccine using M2SR as a vector for the SARS-CoV-2 receptor binding domain. The technology is exclusively licensed from the University of Wisconsin-Madison via WARF and was developed in the laboratories of co-founders Dr. Yoshihiro Kawaoka and Dr. Gabriele Neumann. FluGen operates a clinical-stage enterprise GTM motion centered on government and institutional partnerships — primarily with the U.S. Department of Defense and NIH/NIAID — which provide both non-dilutive grant funding and clinical trial collaboration infrastructure.

FluGen remains pre-revenue with no commercially approved products. Operations have been funded primarily through venture capital (most notably a $12 million Series A in 2015 led by Venture Investors LLC) and federal grants (including a $14.4 million Department of Defense award in October 2017 and additional DoD funding in 2021). Target customer segments for eventual commercialization are older adults aged 65+, pediatric populations aged 6 months to 17 years, and the general population, with distribution expected to flow through government procurement channels and healthcare provider networks upon regulatory approval.

FluGen firmographics

Firmographics
Name
FluGen
Legal name
FluGen, Inc.
Website
https://flugen.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
FluGen is a clinical-stage biopharmaceutical company developing intranasal influenza vaccines using its proprietary M2SR (M2 Deleted Single Replication) live virus platform, targeting older adults, pediatric populations, and the general population against seasonal and pandemic influenza strains.
Ownership category
akta.pro rank

FluGen industry classification

Industry
Product category
Influenza Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAEAD
Seasonal & Endemic Vaccines (e.g., Influenza)
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Influenza vaccine development
  • Intranasal vaccine platform
  • Universal flu vaccine
  • Vaccine clinical trials
  • Biopharmaceutical research

Where FluGen is headquartered

Location

Headquarters

HQ city
Madison
HQ country
United States
HQ region
North America

Offices1 record

Markets served

FluGen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Vaccine Development and Commercialization: Pre-revenue clinical-stage company developing influenza vaccines. Revenue will be generated through vaccine product sales following regulatory approval. The company is developing multiple vaccine candidates including M2SR monovalent and quadrivalent formulations, as well as bivalent COVID/Influenza combination vaccines.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

FluGen product offering

Product offering

Core offering

FluGen is a clinical-stage biopharmaceutical company developing the M2SR (M2 Deleted Single Replication) vaccine platform, a live, replication-deficient influenza virus delivered as an intranasal spray that stimulates mucosal, humoral, and cellular immunity. The company is advancing multiple vaccine candidates including a universal supra-seasonal influenza vaccine (formerly branded RedeeFlu), a quadrivalent M2SR formulation, an H5N1 avian influenza vaccine, and a bivalent COVID-19/influenza combination vaccine using M2SR as a vector platform.

Product overview

FluGen is a clinical-stage vaccine company developing M2SR (M2 Deficient Single Replication), a live intranasal vaccine platform that works differently from standard flu vaccines. The flagship M2SR vaccine (also branded as RedeeFlu) stimulates mucosal, humoral, and cellular immunity and has demonstrated unprecedented protection across seven years of virus drift. The company is also leveraging M2SR as a vector platform for a bivalent COVID-19/Influenza combination vaccine. The development pipeline includes quadrivalent influenza vaccine formulations and M2SR variants targeting H5N1 avian influenza.

Differentiator

Problem solved

Functional benefit

Brands

  • M2SR: M2 Deleted Single Replication live virus vaccine technology - the company's flagship supra-seasonal intranasal influenza vaccine candidate
  • RedeeFlu

Products and services

  • M2SR Vaccine Platform

Quantifiable outcome

  • M2SR demonstrated protection against infection and illness across seven years of virus drift in Phase 2 challenge study
  • +2 more outcomes

Companies that use FluGen

Customer profile

Segments3 records

Ideal customer profiles3 records

FluGen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

FluGen partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • National Institute of Allergy and Infectious Diseases (NIAID) - CIVICs ProgramcoreStrategic or Co-development Partner · 1 January 2021Pediatric clinical trial funded by NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) program. Study conducted at University of Maryland, Duke University, Vanderbilt University, and University of Iowa to evaluate M2SR in children ages 6 months to 17 years.
  • Bharat BiotechminorStrategic or Co-development Partner · 2 April 2020International collaboration with Bharat Biotech to develop CoroFlu, a coronavirus vaccine candidate. Part of broader efforts to apply M2SR technology platform to COVID-19.
  • ArecorminorStrategic or Co-development Partner · 1 July 2013Partnership with UK-based Arecor to develop stable formulation for RedeeFlu vaccine using Arecor's Arestat formulation technology. Funded by UK's Technology Strategy Board Smart programme to improve storage, distribution, and nasal delivery stability.
  • Wisconsin Alumni Research Foundation (WARF)coreStrategic or Co-development Partner · 8 May 2008WARF exclusively licensed FluGen's core M2SR influenza vaccine technology from UW-Madison. The technology was invented in the laboratories of Dr. Yoshihiro Kawaoka and Dr. Gabriele Neumann at UW-Madison and licensed to FluGen.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

FluGen competitors and assessment

Company assessment

Direct peers

  • Vaxart: Clinical-stage biotech developing oral tablet flu vaccines using a non-replicating adenoviral vector platform. Like FluGen, Vaxart pursues mucosal immunity against influenza via an alternative delivery route (oral vs. intranasal) and targets both seasonal and pandemic indications.
  • BiondVax Pharmaceuticals: Israel-based clinical-stage developer of M-001, a recombinant universal flu vaccine candidate targeting conserved epitopes across influenza strains. BiondVax is the most direct competitor in the 'universal influenza vaccine' category alongside FluGen's M2SR.

Emerging players

  • Vaccitech: Clinical-stage vaccine company spun out of Oxford University developing T-cell based influenza vaccines and other immunotherapies. Pursues broader cellular immunity against influenza, paralleling FluGen's cellular-immunity-driven approach with M2SR.
  • Medicago (Mitsubishi Tanabe Pharma): Plant-derived virus-like particle (VLP) vaccine developer with influenza candidates including a quadrivalent flu vaccine. Medicago pursues alternative vaccine production platforms similar to FluGen's novel M2SR approach.

Broad incumbents

  • Novavax: Public clinical-stage/commercial vaccine company using recombinant nanoparticle technology. Novavax's Matrix-M adjuvanted flu vaccine candidate competes in the broader enhanced-immunity influenza space that FluGen targets with M2SR.
  • Moderna: mRNA vaccine leader advancing multiple influenza vaccine candidates including mRNA-1010 and combination flu/COVID programs. Moderna's mRNA flu pipeline represents the most significant emerging competitive threat to FluGen's next-generation influenza approach.
  • Sanofi Pasteur: World's largest influenza vaccine manufacturer producing Fluzone High-Dose and other standard-of-care flu vaccines. Sanofi's established manufacturing, distribution, and physician relationships represent the dominant incumbent FluGen must displace to capture market share.
  • CSL Seqirus: Major influenza vaccine manufacturer and developer of Fluad (MF59-adjuvanted vaccine) and cell-based flu vaccines. CSL Seqirus is a key incumbent competitor in enhanced-immunity influenza vaccines targeting older adults.
  • AstraZeneca (MedImmune): Owner of FluMist, the established intranasal live attenuated influenza vaccine. AstraZeneca is the most direct existing competitor in the intranasal flu vaccine category where FluGen's M2SR is positioned.

Regional players

  • Bharat Biotech: India-based vaccine manufacturer and direct FluGen partner for the CoroFlu (COVID/Influenza) combination vaccine. Bharat Biotech is also an independent developer of influenza and other vaccines, making it both a peer and a commercial partner.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

FluGen social profiles

Digital presence

FluGen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FluGen leadership team

Management profile

Number of profiles

Profiles7 records

FluGen funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FluGen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FluGen

What does FluGen do?

FluGen is a clinical-stage biopharmaceutical company developing the M2SR (M2 Deleted Single Replication) vaccine platform, a live, replication-deficient influenza virus delivered as an intranasal spray that stimulates mucosal, humoral, and cellular immunity. The company is advancing multiple vaccine candidates including a universal supra-seasonal influenza vaccine (formerly branded RedeeFlu), a quadrivalent M2SR formulation, an H5N1 avian influenza vaccine, and a bivalent COVID-19/influenza combination vaccine using M2SR as a vector platform.

Is FluGen a public or private company?

FluGen is a private company. It is classified as venture growth investor backed and is currently operating.

When was FluGen founded?

FluGen was founded in 2007. It employs 1 to 10 people.

Where is FluGen based?

FluGen is headquartered in Madison, United States, in the North America region.

How does FluGen make money?

One revenue line is on record: vaccine Development and Commercialization.

Who are FluGen's main competitors?

Direct peers on record are Vaxart and BiondVax Pharmaceuticals. Emerging players are Vaccitech and Medicago (Mitsubishi Tanabe Pharma). Broad incumbents are Novavax, Moderna, Sanofi Pasteur, CSL Seqirus and AstraZeneca (MedImmune). Bharat Biotech is listed as a regional player.

Does FluGen have an API?

No public API is recorded for FluGen.

What industry is FluGen in?

FluGen's product category is Influenza Vaccines. Its primary akta.pro industry code is HLAIAEAD, Seasonal & Endemic Vaccines (e.g., Influenza), with a secondary code of HLAIAEAF, Pandemic Preparedness & Rapid-Response Vaccines. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Daily CardinalUW-Madison researchers helped create new flu vaccine with promising resultsFluGen, in collaboration with University of Wisconsin-Madison researchers, has developed a new intranasal influenza vaccine candidate that is currently undergoing clinical trials. The vaccine utilizes a modified live virus to prevent cell-to-cell spread and has shown dramatic reductions in infection rates among over 700 trial subjects. FluGen CEO Paul Radspinner estimates the product could reach the market by the 2027-28 flu season.ThelancetSafety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65–85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trialA phase 1b trial evaluated the safety and immunogenicity of an intranasal H3N2 M2-deficient single-replication influenza vaccine, administered alone or co-administered with Fluzone High-Dose Quadrivalent, in adults aged 65–85 years in the USA. The study was conducted by FluGen in collaboration with various clinical research organizations across multiple US sites. Results were published in July 2024 to assess potential improvements in influenza protection for older adults.Clinical Trials ArenaFluGen’s intranasal flu vaccine boosts flu shot efficacyFluGen published Phase Ib trial results showing that its intranasal M2SR vaccine, when combined with Sanofi’s Fluzone HD, increases the efficacy of the inactivated influenza vaccine. The study enrolled 305 participants aged 65-85 and was funded by the US Department of Defense, with data published in The Lancet. This combination approach aims to provide total coverage by invoking mucosal antibodies alongside standard blood antibody responses.Respiratory TherapyPower of Intranasal Flu Vaccine and High-Dose Shot for SeniorsFluGen's investigational intranasal M2SR flu vaccine, when co-administered with Sanofi’s Fluzone High Dose, demonstrated superior protection and enhanced antibody responses in adults aged 65-85 compared to the high-dose shot alone. The study, funded by the US Department of Defense, indicates that this combination could offer robust defense against seasonal flu and potential future pandemics by addressing limitations of current injectable vaccines.GlobeNewswirePredictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu VaccinePredictive Oncology and FluGen announced a collaboration to develop a stable intranasal flu vaccine, supported by a $6.2 million Phase 2B grant from the U.S. Department of Defense. Predictive Oncology will use its biologics team to create a refrigerated-stable formulation, addressing the need for longer shelf-life to support global distribution.Business InsiderPredictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu VaccinePredictive Oncology and FluGen announced a collaboration to develop a stable intranasal flu vaccine, supported by a $6.2 million Phase 2B grant from the U.S. Department of Defense. The company will use its biologics team to create a refrigerated-stable formulation, aiming to extend shelf-life for global distribution.GlobeNewswirePredictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu VaccinePredictive Oncology Inc. and FluGen have announced a collaboration to develop a stable formulation for FluGen's intranasal M2SR flu vaccine, supported by a $6.2 million Phase 2B grant from the U.S. Department of Defense. Predictive Oncology will utilize its proprietary design of experiments and biologics team to ensure the vaccine remains soluble and stable in refrigerated conditions to support global distribution. This partnership aims to extend the vaccine's shelf-life and facilitate its advancement through clinical trials.Stock TitanPredictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu VaccinePredictive Oncology Inc. has entered a collaboration with FluGen to develop a stable formulation for an intranasal flu vaccine, supported by a $6.2 million Phase 2B grant from the U.S. Department of Defense. Predictive Oncology will utilize its proprietary design of experiments to ensure the M2SR vaccine remains soluble and stable in refrigerated conditions to support global distribution. This partnership aims to advance clinical trials for a first-of-its-kind vaccine that offers longer shelf-life and broader protection against virus drift.PR NewswireNew Data Published in the Journal of Infectious Diseases Demonstrate FluGen's M2SR Vaccine Candidate Substantially Enhances Mucosal & Serum Antibodies Against Drifted Influenza StrainsFluGen, Inc. announced the publication of Phase 1B clinical trial data in the Journal of Infectious Diseases demonstrating that its intranasal M2SR H3N2 influenza vaccine candidate substantially enhanced mucosal and serum antibodies against highly drifted influenza strains. The study showed that a single 109 TCID50 dose generated ≥4-fold HAI seroconversion in 71% of recipients, with 80.6% showing ≥2-fold increase in MN antibodies against the Belgium2015 challenge strain. The company stated the vaccine may provide significant advantages over existing injected influenza vaccines by addressing antigenic drift, a long-standing challenge in influenza vaccination.PR NewswireFluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older AdultsFluGen, Inc. announced the dosing of its first subject in a Phase 1b clinical trial combining its intranasal M2SR flu vaccine with a high-dose inactivated flu vaccine in adults aged 65-85 years, funded by the U.S. Department of Defense. The randomized, double-blind study will enroll 300 subjects across four cohorts evaluating safety, tolerability, and immunological response to the vaccines administered alone and concomitantly, with topline data expected in the second half of 2022. The novel approach of combining intranasal and intramuscular vaccine delivery aims to stimulate mucosal, cellular, and antibody immunity to potentially improve efficacy against matched and drifted flu strains in a population highly vulnerable to influenza mortality.